METHOCARBAMOL | N011790 | HIKMA PHARMACEUTICALS USA INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| N/A | Active | Northwestern University | 126 | 2021-09-30 → 2026-12 | |
| Phase 4 | Active | Prisma Health-Upstate | 164 | 2022-06-23 → 2027-12 | |
| Phase 3 | Not Yet Recruiting | University of California, San Francisco | 474 | 2026-10-01 → 2029-12-01 | |
| Phase 4 | Not Yet Recruiting | Wake Forest University Health Sciences | 282 | 2026-10 → 2027-02 | |
| Phase 4 | Completed | Medical College of Wisconsin | 153 | 2015-09 → 2018-08 | |
| Phase 3 | Completed | Boehringer Ingelheim | 80 | 2016-07-27 → 2016-10-19 | |
| Phase 4 | Completed | Montefiore Medical Center | 240 | 2016-03 → 2017-05 | |
| Phase 3 | UNKNOWN | Tanta University | 200 | 2017-04-01 → 2020-12 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$26.38
Highest Price
$26.38
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 00641-6103-10ROBAXIN 100MG/ML INJ | $26.38 | Big4 | Hikma Pharmaceuticals USA Inc. | 08/14/2026 |
| 00641-6103-10ROBAXIN 100MG/ML INJ | $26.38 | FSS | Hikma Pharmaceuticals USA Inc. | 08/14/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
8 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| May 4, 2004 | SUPPL -46 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.